146 related articles for article (PubMed ID: 18246048)
1. Jab1 is overexpressed in human breast cancer and is a downstream target for HER-2/neu.
Hsu MC; Chai CY; Hou MF; Chang HC; Chen WT; Hung WC
Mod Pathol; 2008 May; 21(5):609-16. PubMed ID: 18246048
[TBL] [Abstract][Full Text] [Related]
2. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.
Hsu MC; Chang HC; Hung WC
Endocr Relat Cancer; 2007 Sep; 14(3):655-67. PubMed ID: 17914096
[TBL] [Abstract][Full Text] [Related]
3. Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells.
Shackleford TJ; Zhang Q; Tian L; Vu TT; Korapati AL; Baumgartner AM; Le XF; Liao WS; Claret FX
Breast Cancer Res; 2011 Jun; 13(3):R65. PubMed ID: 21689417
[TBL] [Abstract][Full Text] [Related]
4. Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer.
Wang J; Barnes RO; West NR; Olson M; Chu JE; Watson PH
Breast Cancer Res; 2008; 10(3):R51. PubMed ID: 18534028
[TBL] [Abstract][Full Text] [Related]
5. Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of β-catenin and STAT1 in chronic myeloid leukemia cells.
Yang KT; Wang MC; Chen JY; Hsu MC; Hung WC
J Cell Physiol; 2011 Nov; 226(11):2849-56. PubMed ID: 21935931
[TBL] [Abstract][Full Text] [Related]
6. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):886-900. PubMed ID: 30282449
[TBL] [Abstract][Full Text] [Related]
7. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ; Sahin AA; Rassidakis GZ; Yuan LX; Smith TL; Yang Y; Gilcrease MZ; Cristofanilli M; Nahta R; Pusztai L; Claret FX
Clin Cancer Res; 2003 Nov; 9(15):5652-9. PubMed ID: 14654548
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.
Wang H; Liu XB; Chen JH; Wang QQ; Chen JP; Xu JF; Sheng CY; Ni QC
Exp Mol Pathol; 2014 Oct; 97(2):191-201. PubMed ID: 25036402
[TBL] [Abstract][Full Text] [Related]
9. Let-7d Inhibits Growth and Metastasis in Breast Cancer by Targeting Jab1/Cops5.
Wei Y; Liu G; Wu B; Yuan Y; Pan Y
Cell Physiol Biochem; 2018; 47(5):2126-2135. PubMed ID: 29975923
[TBL] [Abstract][Full Text] [Related]
10. Cytoplasmic localization of Jab1 and p27 Kip1 might be associated with invasiveness of papillary thyroid carcinoma.
Ahn J; Hong SA; Lee SE; Kim J; Oh YS; Park SJ; Chung YJ
Endocr J; 2009; 56(5):707-13. PubMed ID: 19461157
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
[TBL] [Abstract][Full Text] [Related]
12. Jab1-siRNA Induces Cell Growth Inhibition and Cell Cycle Arrest in Gall Bladder Cancer Cells via Targeting Jab1 Signalosome.
Pandey P; Siddiqui MH; Behari A; Kapoor VK; Mishra K; Sayyed U; Tiwari RK; Shekh R; Bajpai P
Anticancer Agents Med Chem; 2019; 19(16):2019-2033. PubMed ID: 31345154
[TBL] [Abstract][Full Text] [Related]
13. The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression.
Tomoda K; Kato JY; Tatsumi E; Takahashi T; Matsuo Y; Yoneda-Kato N
Blood; 2005 Jan; 105(2):775-83. PubMed ID: 15353483
[TBL] [Abstract][Full Text] [Related]
14. S100A7, Jab1, and p27
Granata M; Skarmoutsou E; Gangemi P; Mazzarino MC; D'Amico F
J Cell Biochem; 2019 Mar; 120(3):3384-3392. PubMed ID: 30203426
[TBL] [Abstract][Full Text] [Related]
15. Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.
Larsen SS; Egeblad M; Jäättelä M; Lykkesfeldt AE
Breast Cancer Res Treat; 1999 Nov; 58(1):41-56. PubMed ID: 10634517
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
[TBL] [Abstract][Full Text] [Related]
17. Gfer inhibits Jab1-mediated degradation of p27kip1 to restrict proliferation of hematopoietic stem cells.
Teng EC; Todd LR; Ribar TJ; Lento W; Dimascio L; Means AR; Sankar U
Mol Biol Cell; 2011 Apr; 22(8):1312-20. PubMed ID: 21346186
[TBL] [Abstract][Full Text] [Related]
18. Jab1 promotes glioma cell proliferation by regulating Siah1/β-catenin pathway.
Zhu Y; Qiu Z; Zhang X; Qian F; Wang B; Wang L; Shi H; Yu R
J Neurooncol; 2017 Jan; 131(1):31-39. PubMed ID: 27640199
[TBL] [Abstract][Full Text] [Related]
19. The novel Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces apoptosis in human breast cancer cells.
Xiao H; Claret FX; Shen Q
Neoplasma; 2019 May; 66(3):481-486. PubMed ID: 30868895
[TBL] [Abstract][Full Text] [Related]
20. Adhesion to fibronectin induces p27(Kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells.
Fei M; Hang Q; Hou S; He S; Ruan C
Mol Cell Biochem; 2014 Jan; 386(1-2):177-87. PubMed ID: 24170542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
